Literature DB >> 12086882

Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.

Charles L Sawyers1.   

Abstract

Pharmacologic inhibition of the Bcr-Abl tyrosine kinase in human chronic myeloid leukemia leads to dramatic clinical responses, but relapses occur in advanced stage patients. New findings about Abl kinase domain regulation provide insight into novel strategies for targeted therapy.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12086882     DOI： 10.1016/s1535-6108(02)00022-3

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  13 in total

Review 1.  RET TKI: potential role in thyroid cancers.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia Martina Ferrari; Caterina Mancusi; Michele Colaci; Libero Santarpia; Clodoveo Ferri
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 2.  BH3 mimetics to improve cancer therapy; mechanisms and examples.

Authors:  Lin Zhang; Lihua Ming; Jian Yu
Journal:  Drug Resist Updat       Date:  2007-10-24       Impact factor: 18.500

3.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

4.  Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.

Authors:  Lan Zhou; Naili An; Rex C Haydon; Qixin Zhou; Hongwei Cheng; Ying Peng; Wei Jiang; Hue H Luu; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Benjamin Breyer; Tong-Chuan He
Journal:  Cancer Lett       Date:  2003-04-25       Impact factor: 8.679

5.  Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Authors:  Frank E Kwarcinski; Kristoffer R Brandvold; Sameer Phadke; Omar M Beleh; Taylor K Johnson; Jennifer L Meagher; Markus A Seeliger; Jeanne A Stuckey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2016-03-01       Impact factor: 5.100

6.  SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.

Authors:  Jing Chen; Wen-Mei Yu; Hanako Daino; Hal E Broxmeyer; Brian J Druker; Cheng-Kui Qu
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

7.  Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.

Authors:  Wen-Hsing Cheng; Cayetano von Kobbe; Patricia L Opresko; Kesha M Fields; Jian Ren; Donald Kufe; Vilhelm A Bohr
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  A peptide biosensor for detecting intracellular Abl kinase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Ekaterina A Placzek; Michael P Plebanek; Andrew M Lipchik; Stephanie R Kidd; Laurie L Parker
Journal:  Anal Biochem       Date:  2009-10-07       Impact factor: 3.365

9.  A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

Authors:  Ding Wu; Michael R Mand; Darren R Veach; Laurie L Parker; Bayard Clarkson; Stephen J Kron
Journal:  Anal Biochem       Date:  2007-12-25       Impact factor: 3.365

10.  Small molecule recognition of c-Src via the Imatinib-binding conformation.

Authors:  Arvin C Dar; Michael S Lopez; Kevan M Shokat
Journal:  Chem Biol       Date:  2008-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.